Smarter™ 7 × 19 CAR Construction Service

CAR engineered T cell therapy has developed rapidly in recent years. Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against solid tumors has lagged, potentially due to insufficient CAR-T cell expansion and persistence. To improve CAR-T cell efficacy, Creative Biolabs is proud to present a new generation CAR-T cells to express interleukin (IL)-7 and CCL19 (7 × 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs, with superior anti-tumor activity compared to conventional CAR-T cells.

Introduction of 7 × 19 CAR

Studies have shown that IL-7 and CCL19 are produced by T-region fibroblast reticulocytes, which are essential for the formation and maintenance of T-cell regions in lymphoid organs, in which T cells and DCs can be recruited from the periphery. Therefore, to improve CAR-T cell efficacy, we develop potent functional elements based on IL-7 and CCL19 signaling domains, which can mimic the function of T-zone reticular cells, and recruit T cells and DCs to tumor tissues to improve the therapeutic effect of CAR-T cells against solid tumors.

To obtain 7 × 19 CAR constructs, we generate a tandem construct encoding the CAR, IL-7, and CCL19 with two 2A peptide sequence between the genes. This novel, regulatable 7 × 19 system may promote the infiltration of dendritic cells (DC) and T cells into tumor tissues.

Features of our 7 × 19 CAR Service

• Strong efficacy in both solid and liquid tumors with greater tumor penetration
• Improved safety profile including moderate cytokine secretion and decreased off-tumor toxicity
• Excellent expert team for offering real-time technical guidance
• Advanced assay platforms to promote the data output
• Timely data feedback to facilitate the process of your project

Creative Biolabs is a leading company which is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes. Through our full spectrum of early discovery, nonclinical and commercialization services, we are committed to developing the most promising CAR-T cell therapy product candidate for our clients.

For more detailed information, please feel free to contact us or directly send us an inquiry.